Literature DB >> 30320345

Downregulation of cyclooxygenase‑1 stimulates mitochondrial apoptosis through the NF‑κB signaling pathway in colorectal cancer cells.

Lei Ding1, Huan Gu1, Zhenwei Lan1, Qingchun Lei2, Wenxue Wang1, Jiangfei Ruan1, Min Yu1, Jie Lin3, Qinghua Cui1.   

Abstract

The prognosis of patients with colorectal cancer (CRC) remains poor owing to diagnosis typically occurring at advanced stages of the disease. The understanding of the molecular regulatory signatures of CRC may lead to the identification of biomarkers for the early detection, prevention and clinical intervention of CRC. Epidemiological studies have indicated that cyclooxygenase‑1 (COX‑1) serves an active function in colon carcinogenesis. However, the molecular mechanism underlying COX‑1 regulation in CRC remains unknown. In the present study, COX‑1 was identified to be markedly upregulated in colorectal tissues of patients with CRC, and in the CRC cell lines HCT116 and HT29. To determine the function of COX‑1 in cancer development, short hairpin RNA knockdown of COX‑1 was employed in HCT116 and HT29 CRC cells in the present study. The results demonstrated that silencing of COX‑1 depolarized the mitochondrial membrane potential, inhibited adenosine triphosphate production, induced the generation of intracellular reactive oxygen species and triggered caspase‑dependent mitochondrial apoptosis. Furthermore, depletion of COX‑1 suppressed anti‑apoptotic B‑cell lymphoma 2 and enhanced pro‑apoptotic Bcl‑2‑associated X protein expression by inhibiting the p65 subunit phosphorylation of nuclear factor κB (NF‑κB). Taken together, the results of the present study indicated that COX‑1 inhibition significantly triggered cell death by destroying the mitochondrial function that is associated with deactivation of the NF‑κB signaling pathway. These results suggest COX‑1 as a potential anticancer target in CRC.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30320345     DOI: 10.3892/or.2018.6785

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  Knockdown of Microtubule Associated Serine/threonine Kinase Like Expression Inhibits Gastric Cancer Cell Growth and Induces Apoptosis by Activation of ERK1/2 and Inactivation of NF-κB Signaling.

Authors:  Cai-Xia An; Shou-Pin Xie; Hai-Long Li; Yong-Hua Hu; Rong Niu; Lin-Jie Zhang; Yan Jiang; Qiang Li; Yong-Ning Zhou
Journal:  Curr Med Sci       Date:  2021-02-13

2.  Diclofenac down-regulates COX-2 induced expression of CD44 and ICAM-1 in human HT29 colorectal cancer cells.

Authors:  Çağatay Yilmaz; Sadi Köksoy; Tuğçe Çeker; Mutay Aslan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-08-26       Impact factor: 3.195

Review 3.  MicroRNAs Involved in Carcinogenesis, Prognosis, Therapeutic Resistance and Applications in Human Triple-Negative Breast Cancer.

Authors:  Lei Ding; Huan Gu; Xianhui Xiong; Hongshun Ao; Jiaqi Cao; Wen Lin; Min Yu; Jie Lin; Qinghua Cui
Journal:  Cells       Date:  2019-11-22       Impact factor: 6.600

Review 4.  Research Progress on the Relationship Between Inflammation and Colorectal Cancer.

Authors:  Feng Zhang; Song Qiao
Journal:  Ann Gastroenterol Surg       Date:  2021-11-10

Review 5.  The Role of Mitochondria Dysfunction in Inflammatory Bowel Diseases and Colorectal Cancer.

Authors:  Patrycja Kłos; Siarhei A Dabravolski
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

Review 6.  Extracellular Vesicle-Mediated Mitochondrial Reprogramming in Cancer.

Authors:  Roger Carles-Fontana; Nigel Heaton; Elena Palma; Shirin E Khorsandi
Journal:  Cancers (Basel)       Date:  2022-04-07       Impact factor: 6.575

7.  Swertia mussotii prevents high-fat diet-induced non-alcoholic fatty liver disease in rats by inhibiting expression the TLR4/MyD88 and the phosphorylation of NF-κB.

Authors:  Ming Dong Si; Meng Wu; Xi Zhen Cheng; Zhi Hong Ma; Yu Guang Zheng; Jing Li; Si Li; Yong Xing Song; Donglai Ma
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.